Spacific features and deatils pf the resolution Plan as apprpved by the NCLT
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kobo Biotech Ltd's resolution plan submitted by Beaufond Industries Limited has been approved by the NCLT Hyderabad Bench on May 11, 2026. Under the plan, Beaufond Industries (net worth INR 333.18 crores) will amalgamate with Kobo Biotech and then demerge, with Beaufond PLC becoming the new promoter holding 57.23% stake. Financial creditors will receive INR 67.78 crores plus 3% equity upside, while total resolution amount is INR 70.11 crores. Existing public shareholders will be diluted from 55.05% to just 2% of the post-merger share capital. The company had pre-CIRP net worth of INR 132.91 crores and total assets of INR 71.39 crores as of March 2024. All existing liabilities will be extinguished post-implementation.
Positive for creditors who will receive payment. Existing public shareholders face significant dilution from 55% to 2%, while Beaufond PLC gains majority control at 57.23%. The stock may see volatility as the new promoter group takes over.